Glaucoma Prognostication Platform

More than 80 million people worldwide suffer from glaucoma, an asymptomatic and irreversible disease of the optic nerve leading to blindness unless intra-ocular pressure (IOP) is controlled. IOP is the only controllable risk factor to stabilize patients, and various therapeutic options exist to reduce IOP. IOP follows, however, individual nycthemeral patterns and cannot be effectively monitored with current devices leading to therapeutic failure and progression visual function loss amongst about one in three glaucoma patients. SENSIMED AG has developed Triggerfish, a wearable non-invasive solution that captures spontaneous dimensional changes at the corneoscleral area. The purpose of the Glaucoma Prognostication Platform is to provide a machine learning platform for 24h profiles of ocular dimensional changes to predict the progression of glaucoma.